ProPhase Labs, Inc. (NASDAQ:PRPH) Q3 2022 Earnings Conference Call November 10, 2022 11:00 AM ET

Company Participants

Ted Karkus – Chairman and Chief Executive Officer

Conference Call Participants

Fred McDonald – Private Investor

Yi Chen – H.C. Wainwright

Dennis Waldman – Barrett Productions, LLC

Patrick Patterson – Investor

Operator

Good morning, afternoon, evening, and welcome to the ProPhase Labs Third Quarter 2022 Financial Results Conference Call. All participants will be in listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note, this event is being recorded.

I would now like to turn the [Audio Dip] Karkus, Chairman and CEO of ProPhase Labs. Please go ahead.

Ted Karkus

Thanks very much, and thank you everyone for joining me today. I will start with the forward-looking statements. Then I'm not going to read our third quarter press release. You're all capable of doing that yourself. I will go through some highlights for maybe I don't know how long, 15 or 20 minutes. And then hopefully, please don't be shy, ask questions. I do these virtual non-deal roadshows every few weeks where I usually present the whole company for 25 minutes.

And then we have a very lively 35 minute Q&A. So I hope people on the call will ask some questions so I can get into more details on various topics regarding our company. As always, I have to start with a forward-looking statement. This presentation contains forward-looking statements related to our strategy and business objectives.

All statements other than statements of historical facts, included this presentation, may be deemed to be forward-looking statements, including statements regarding our strategy, plans, objectives and initiatives, including those related to our plans to expand our in-house clinical testing capabilities and genomics testing offering, and our plan to develop Equivir, Equivir and Linebacker.

You can identify forward-looking statements by words such as anticipate, believe, could estimate, expect, intent, may, plan, potential, predict, project, should, will, would, or the negative of those terms and similar expressions that convey uncertainty or future events or outcomes.

These forward-looking statements involved known and unknown risks, uncertainty, and other factors that may cause our actual results, performance, or achievements to be materially different from those contemplated, projected, forecasted, estimated or budgeted whether express or implied by these forward-looking statements including risks related to consumer demands for a diagnostic and genomic services. The competitive environment, challenges relating to entering into new business lines, the failure to obtain and maintain certain regulatory approvals, our ability to collect payments for the diagnostic tests we deliver, including our ability to collect payments from uninsured individuals of emergency funding is not allocated to HRSA uninsured program in the future and our ability to continue executing our business plan.